TMT Newswire > GlobeNewswire
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

Data selected for oral presentation reinforce previous findings on safety and efficacy

MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, from October 14th-19th, including an oral presentation at the 'Research Pipeline: New Findings on Therapeutics” session featuring data generated utilizing the NeuroStar TMS (transcranial magnetic stimulation) System. In addition, NeuroStar will exhibit at booth #416, where demonstrations of the device will be given.

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here